National Survey on Dyslipidemic Patients

Completed

• Conditions: Dyslipidemia

• Registration Number: NCT00701402
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-06-18
• Study First Submitted QC: 2008-06-18
• Study First Posted: 2008-06-19
• Study Completion: 2009-01
• Status Verified: 2009-08
• Last Update Submitted: 2009-08-04
• Last Update Posted: 2009-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3655

Inclusion Criteria

• Diagnosis of dyslipemia made less than 2 years
• Treated by a lipid-lowering drug
• Agree to take part in the survey

Read More

Exclusion Criteria

• Patient included in a clinical trial

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention).	Once

Trial Locations

Locations (1)

Research Site; 🇫🇷 Yquelon, France